Preface – EANM 2022 © private - Oana C. Kulterer, MD, Division of Nuclear Medicine, Department of Biomedical Imaging and ­Image-Guided Therapy, Medical University Vienna, Vienna, Austria Dear Colleagues, After two years of virtual events, the nuclear medicine and oncology communities were excited to meet each other in person at the 35th Annual Congress of the European Association of Nuclear Medicine, held in Barcelona, Spain, and virtually from 15th – 19th October 2022. The event has cele

Latest developments in prostate cancer treatment Favorable complementary mechanisms: 223RaCl2 followed by 177Lu-PSMA (RALU) The positive efficacy and safety data of 177Lu-PSMA-617 in the treatment of mCRPC patients from the Lu-PSMA and VISION trials led to its FDA approval and designation as a breakthrough therapy for later lines of mCRPC treatment [1,2].

Neuroendocrine tumor imaging updates Little impact of interim PET/CT staging during PRRT for NETs Guideline recommendations for peptide receptor radionuclide therapy (PRRT) using 177Lu- DOTA-0-Tyr3-Octreotate (DOTATATE) in patients with neuroendocrine tumors (NETs) include 3-5 cycles with a dose ranging from 5.5-7.4 GBq per cycle with 6-12 weeks intervals [1].

Advances in PSMA radiotracers for prostate cancer imaging [18F]DCFPyL tops [18F]Flurocholine in the recurrent setting: PYTHON Prostate-specific membrane antigen (PSMA)-targeting positron emission tomography/computed tomography (PET/CT) imaging is increasingly used to characterize prostate cancer (PCa).